Book a Meeting

Non-Fucosylated Anti-Human PD-1 (Dostarlimab) Therapeutic Antibody (CAT#: BioBet-1790ZP) Datasheet

Target
PD-1
Isotype
IgG
Description
Non-Fucosylated Anti-Human PD-1 (Dostarlimab) is a glycosylation-modified therapeutic biobetter antibody.
Antibody Indication
Endometrial cancer
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced PD-1 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
PDCD1
Full Name
Programmed Cell Death 1
Background
This gene encodes a cell surface membrane protein of the immunoglobulin superfamily. This protein is expressed in pro-B-cells and is thought to play a role in their differentiation. In mice, expression of this gene is induced in the thymus when anti-CD3 antibodies are injected and large numbers of thymocytes undergo apoptosis. Mice deficient for this gene bred on a BALB/c background developed dilated cardiomyopathy and died from congestive heart failure. These studies suggest that this gene product may also be important in T cell function and contribute to the prevention of autoimmune diseases. [provided by RefSeq, Jul 2008]
Alternative Names
Pidilizumab;1310680-64-8;CT-011;hBat-1;CT-011;PDCD1;programmed cell death 1;programmed cell death protein 1;CD279;PD1;protein PD-1;PD-1;SLEB2;hPD-1;hPD-l;
Gene ID
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
Dostarlimab
Host
Human
Species Reactivity
Human
Description
This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.
Antibody Indication
Endometrial cancer

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.